List of Excipients in Branded Drug FOSAMAX

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Merck Sharp & Dohme Corp	FOSAMAX	alendronate sodium	0006-0031	ANHYDROUS LACTOSE
Merck Sharp & Dohme Corp	FOSAMAX	alendronate sodium	0006-0031	CELLULOSE, MICROCRYSTALLINE
Merck Sharp & Dohme Corp	FOSAMAX	alendronate sodium	0006-0031	CROSCARMELLOSE SODIUM
Merck Sharp & Dohme Corp	FOSAMAX	alendronate sodium	0006-0031	MAGNESIUM STEARATE
Physicians Total Care Inc	FOSAMAX	alendronate sodium	54868-4384	ANHYDROUS LACTOSE
Physicians Total Care Inc	FOSAMAX	alendronate sodium	54868-4384	CELLULOSE, MICROCRYSTALLINE

FOSAMAX Excipient Strategy and Commercial Opportunities for Alendronate Products

Last updated: August 7, 2026

FOSAMAX contains alendronate sodium, an oral bisphosphonate used to treat osteoporosis and other metabolic bone disorders. Its core composition is commercially mature, and the primary compound, formulation, method-of-use, and regulatory exclusivity barriers have expired. Current opportunities are concentrated in excipient optimization, palatability, administration compliance, differentiated dosage forms, combination products, and manufacturing efficiency rather than in basic alendronate composition-of-matter protection.

What is FOSAMAX and which excipients does it use?

FOSAMAX is an oral alendronate product originally developed and marketed by Merck. U.S. products include alendronate tablets, oral solution, and the combination product FOSAMAX Plus D, which contains alendronate sodium and cholecalciferol.

FOSAMAX tablet excipients

The immediate-release tablet formulation uses conventional pharmaceutical excipients. Depending on strength and product version, listed excipients include:

Excipient class	Commercial function
Microcrystalline cellulose	Diluent, compressibility aid
Lactose anhydrous	Diluent and tablet mass builder
Croscarmellose sodium or crospovidone	Disintegrant
Magnesium stearate	Lubricant
Colloidal silicon dioxide	Glidant
Sodium starch glycolate	Disintegrant in selected formulations
Coloring agents	Product identification in selected strengths

The formulation is not designed for sustained release. The principal technical challenge is delivering a highly polar, ionizable bisphosphonate in a solid dosage form while preserving tablet integrity, rapid dispersion, dose uniformity, and low manufacturing cost.

FOSAMAX tablets must be taken with plain water after an overnight fast. Patients must remain upright and avoid food, beverages, and other medicines for a specified period because alendronate has very low gastrointestinal absorption and can cause upper gastrointestinal irritation. The administration requirements create the main commercial opening for excipient-led innovation. [1]

FOSAMAX Plus D excipients

FOSAMAX Plus D combines alendronate sodium with vitamin D3, or cholecalciferol. The product has a different formulation burden because the developer must stabilize both a highly water-soluble ionic drug and a lipophilic vitamin.

Relevant excipient functions include:

• Compressibility and tablet hardness for a relatively high-dose tablet.
• Protection of cholecalciferol from light, oxygen, and moisture.
• Uniform distribution of the low-dose vitamin D component.
• Control of disintegration without impairing alendronate release.
• Flavor and swallowability improvements where chewable or dispersible formats are pursued.

The combination product has greater formulation complexity than plain alendronate but remains exposed to generic substitution and alternative vitamin D combinations.

What excipient problems create commercial opportunities for alendronate?

The most valuable opportunities address administration burden rather than simply replacing one standard filler with another.

Improving tablet swallowability

Alendronate tablets are relatively large for chronic-use products. Tablet size, surface roughness, hardness, and post-dose esophageal exposure affect adherence. Excipient systems can support:

• Lower tablet mass through higher-functionality fillers.
• Improved compactability at lower compression force.
• Smoother tablet surfaces.
• Faster wetting and disintegration.
• Orally disintegrating or rapidly dispersing presentations.

Potential platforms include silicified microcrystalline cellulose, co-processed cellulose systems, mannitol-based matrices, low-substituted hydroxypropyl cellulose, and directly compressible polyols. Any new product must preserve dose uniformity and demonstrate acceptable stability.

Reducing gastrointestinal irritation

Alendronate’s gastrointestinal risk is linked to local exposure and administration errors. A formulation that reduces esophageal contact or improves transit could have commercial value, but an excipient cannot be assumed to eliminate the class warning.

Potential strategies include:

• Rapidly dispersing tablets that reduce prolonged esophageal residence.
• Buffered microenvironments that control local pH.
• Film coatings that improve swallowing without delaying intended release.
• Effervescent or reconstitutable systems that encourage administration with adequate water.
• Mucoadhesion avoidance, because prolonged contact with esophageal tissue would be commercially undesirable.

The regulatory burden would be higher for any formulation that changes dissolution, gastric exposure, local tolerability, or administration instructions.

Improving palatability for liquid and pediatric-style formats

FOSAMAX oral solution demonstrates that alendronate can be delivered in a liquid format. A liquid product creates opportunities in taste masking, dosing convenience, and packaging.

Suitable excipient categories include:

• Sweeteners such as sucralose or acesulfame potassium.
• Flavor systems designed for metallic or mineral-like taste.
• Buffer systems that maintain chemical stability.
• Preservatives where the water activity and multidose packaging require them.
• Chelation-control strategies where trace metals could affect stability.
• High-barrier unit-dose packaging.

The product must remain chemically stable and accurately dosed. Taste masking is technically difficult because alendronate is highly ionic and can interact with flavor compounds, sweeteners, or polymeric taste-masking materials.

Stabilizing FOSAMAX Plus D-type combinations

Cholecalciferol is sensitive to oxidation, light, and formulation environment. An excipient strategy for an alendronate-vitamin D product should focus on:

• Antioxidant compatibility.
• Oxygen limitation in the package headspace.
• Light-protective coatings.
• Moisture-control packaging.
• Uniform low-dose vitamin distribution.
• Control of degradation products.

The commercial opportunity is strongest in fixed-dose products that simplify supplementation and improve adherence without increasing tablet burden.

What formulations are protected by FOSAMAX patents?

FOSAMAX’s core patent estate is largely expired in the United States and other major markets.

Subject matter	Representative protection	Status and commercial effect
Alendronate compound and bisphosphonate chemistry	U.S. Patent No. 4,922,007	Expired; no current composition-of-matter barrier
Oral pharmaceutical compositions and therapeutic uses	Merck alendronate patent family	Expired or no longer commercially blocking in the United States
Alendronate plus vitamin D	FOSAMAX Plus D patent and regulatory exclusivity estate	Expired; generic combination competition permitted
Tablet, oral solution, and administration-related claims	Product-specific patents and labeling protections	Generally expired; remaining value depends on unexpired jurisdiction-specific rights
Manufacturing and process claims	Process patents and know-how	Potentially relevant where still enforceable, but generally weaker than compound protection

The alendronate compound patent, U.S. Patent No. 4,922,007, was granted to Merck and is commonly cited as the foundational U.S. patent for alendronate. Its term has expired. Current products therefore compete primarily on price, supply reliability, formulation differentiation, dosage convenience, and regulatory execution.

A new excipient combination can receive patent protection if it has a non-obvious technical effect, such as improved stability, dissolution, bioavailability, taste, or tolerability. A simple substitution of lactose for mannitol, or magnesium stearate for another lubricant, is unlikely to create durable protection without comparative performance data.

When did FOSAMAX lose exclusivity?

FOSAMAX lost meaningful U.S. market exclusivity in stages.

Milestone	Approximate timing	Effect
Alendronate compound patent issued	1990	Established core patent protection
FDA approval of FOSAMAX tablets	1995	Began branded commercial life
Generic alendronate entry	2008 onward	Ended practical compound-level exclusivity
FOSAMAX Plus D approval	2005	Added combination-product competition
Generic alendronate and vitamin D products	Late 2000s onward	Reduced differentiation of the combination product
Current market	2026	Mature generic market with limited brand pricing power

The exact expiration and pediatric or regulatory exclusivity treatment depends on the specific NDA, patent listing, and product strength. The commercial conclusion is stable: FOSAMAX is a legacy product, and excipient innovation must be justified by a new product proposition rather than by protection of the original drug.

What is the Orange Book status of FOSAMAX?

FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly called the Orange Book, identifies the approved reference products and patent or exclusivity information relevant to generic approval. FOSAMAX and FOSAMAX Plus D have been subject to generic competition for many years. The original blocking patents and regulatory exclusivities are not expected to prevent new abbreviated new drug applications for standard alendronate products. [2]

Potential applicants still must address:

• Reference-listed drug selection.
• Strength-specific bioequivalence requirements.
• Drug product quality and dissolution.
• Labeling differences.
• Any currently listed patent with a non-expired term.
• Manufacturing site and supplier controls.
• Product-specific requirements for oral solution or combination formulations.

Orange Book status should be checked by NDA, strength, dosage form, and current publication date because listings and delistings can change.

Which companies are challenging or competing with FOSAMAX?

The competitive field includes generic pharmaceutical manufacturers, private-label suppliers, contract manufacturers, and companies developing alternative osteoporosis therapies.

Generic alendronate competitors

Generic competition has included large-scale manufacturers such as Teva, Sandoz, Mylan/Viatris, Sun Pharma, Dr. Reddy’s, Apotex, and other regional suppliers, depending on market and product strength. Availability varies by country and by whether the product is a tablet, oral solution, or combination with vitamin D.

The commercial characteristics of generic alendronate include:

• Low active pharmaceutical ingredient cost relative to specialty drugs.
• High price sensitivity.
• Multiple approved suppliers.
• Periodic shortages caused by low margins, API concentration, or manufacturing disruption.
• Limited willingness by payers to reimburse premium excipient systems without demonstrated clinical value.

Therapeutic competitors

Alendronate competes with:

• Risedronate.
• Ibandronate.
• Zoledronic acid.
• Denosumab.
• Selective estrogen receptor modulators.
• Anabolic and dual-action osteoporosis medicines.

Long-acting injectables and infusions compete on adherence and dosing frequency. An improved alendronate formulation would need to deliver measurable convenience or tolerability benefits to offset the simplicity of established generic tablets.

How strong is the patent estate for an excipient-based FOSAMAX product?

The legacy FOSAMAX patent estate is weak for blocking purposes but can still provide freedom-to-operate information and prior-art boundaries.

A new product may obtain protection around:

1. Specific excipient ratios.
2. Particle engineering or granulation methods.
3. Taste-masking systems.
4. Moisture- and oxygen-control packaging.
5. Chewable or orally disintegrating dosage forms.
6. Stabilized alendronate-vitamin D compositions.
7. Controlled disintegration or dissolution profiles.
8. Unit-dose liquid presentations.
9. Manufacturing processes that reduce degradation or improve content uniformity.

Patent strength depends on whether the formulation produces an unexpected result. Useful evidence would include comparative dissolution, degradation, tablet robustness, palatability, administration-error reduction, or adherence data.

A formulation patent that covers only a narrow excipient percentage may be easy to design around. A stronger estate would combine composition claims with process, dosage-form, package, and method-of-use claims across the United States, Europe, Japan, and other high-value markets.

What FDA regulatory pathway applies to new FOSAMAX formulations?

A conventional generic alendronate tablet can generally use the ANDA pathway if it matches the reference product in active ingredient, dosage form, strength, route, and relevant performance characteristics. A materially different excipient system may still be approvable through an ANDA if the product meets FDA requirements, but a novel dosage form or clinical claim can push the program toward a 505(b)(2) application.

Product concept	Likely pathway
Conventional generic tablet	ANDA
Same active and strength with improved excipients	Usually ANDA, subject to product-specific requirements
New oral solution with different formulation	ANDA or 505(b)(2), depending on reference and differences
Chewable or orally disintegrating product	Often 505(b)(2) if not substitutable with the reference
New administration method or clinical benefit	505(b)(2) likely
Alendronate with a new vitamin D formulation	ANDA or 505(b)(2), depending on product and claims

FDA will focus on equivalence, dissolution, stability, impurities, excipient safety, manufacturing controls, and labeling. Novel excipients can create a separate safety and regulatory burden, particularly for chronic administration.

What generic launch risks exist for an excipient-focused alendronate product?

The principal launch risks are commercial and technical rather than patent-based.

Risk	Business impact	Mitigation
Commodity pricing	Limits return on a differentiated tablet	Target private-label, payer, or adherence segments
Weak clinical differentiation	Payers may substitute standard generic	Generate tolerability or adherence evidence
Excipient incompatibility	Stability failures or impurities	Conduct forced-degradation and compatibility studies
Low oral bioavailability	Difficult bioequivalence demonstration	Optimize particle size, wetting, and dissolution
Administration-error persistence	Product does not solve patient behavior	Use packaging, instructions, and formulation together
Supplier concentration	Production interruption	Qualify dual sources for API and critical excipients
Combination-product complexity	Vitamin D assay and uniformity failures	Use validated premix or controlled granulation
Patent design-around	Narrow formulation claims lack value	Build layered composition and process claims

A low-cost product based on standard excipients may be commercially rational if manufacturing efficiency is the objective. A premium formulation requires evidence that it reduces discontinuation, improves persistence, or solves a recognized patient problem.

What licensing and partnership opportunities exist?

Licensing opportunities are more likely to arise around enabling technologies than around the FOSAMAX brand.

Potential partners include:

• Generic manufacturers seeking differentiated oral bisphosphonate products.
• Excipient suppliers with co-processed direct-compression systems.
• Taste-masking technology companies.
• Packaging companies offering oxygen- and moisture-barrier unit-dose systems.
• Specialty pharmaceutical companies pursuing osteoporosis lifecycle products.
• Contract development and manufacturing organizations with oral solid-dose capacity.

The most attractive deal structures would involve milestone payments for formulation proof of concept, regulatory acceptance, and commercial launch, with royalties tied to net sales. A license based only on a standard excipient substitution would have limited negotiating leverage.

How does FOSAMAX compare with competing bisphosphonate products?

Product	Active ingredient	Main dosage advantage	Excipient opportunity	Competitive constraint
FOSAMAX	Alendronate	Weekly oral dosing available	Swallowability, rapid dispersion, liquid and combination formats	Low-cost generics
Actonel	Risedronate	Oral alternative with different dosing options	Similar adherence and GI-tolerability opportunities	Generic risedronate
Boniva	Ibandronate	Monthly oral or injectable options	Reduced dosing frequency has greater value than excipient changes	Narrower treatment positioning
Reclast	Zoledronic acid	Annual intravenous dosing	Limited oral excipient relevance	Infusion logistics
Prolia	Denosumab	Six-month injection	Competes primarily on adherence	Biologic and administration cost

FOSAMAX has the largest opportunity for low-cost oral lifecycle innovation because alendronate is widely known, inexpensive, and suitable for multiple dosage forms. Its weakness is that generic competition makes premium pricing difficult.

What are the revenue opportunities for a new alendronate excipient product?

Revenue exposure depends on positioning.

Commodity generic strategy

This approach uses established excipients, efficient manufacturing, and broad distribution. The revenue model depends on volume, supply reliability, and contracts with wholesalers, pharmacy benefit managers, hospitals, and private-label distributors.

Differentiated adherence strategy

A smaller-volume product could target patients who have difficulty swallowing tablets, fail to follow fasting instructions, or discontinue treatment because of gastrointestinal discomfort. Commercial success would require:

• A clear label-compatible benefit.
• Evidence of improved persistence.
• Pharmacist and prescriber adoption.
• Packaging that reinforces correct administration.
• Reimbursement or cash-pay pricing that supports the added cost.

Combination-product strategy

Alendronate with vitamin D remains commercially relevant where supplementation is routine. The product must compete with separate generic alendronate and over-the-counter vitamin D, which creates a substantial price ceiling.

Geographic strategy

The United States has the strongest generic substitution environment and the clearest FDA pathway. Europe and Japan offer opportunities through national reimbursement systems, but formulation and labeling requirements vary. Emerging markets may reward low-cost liquid, dispersible, or combination presentations, although price pressure and local registration requirements remain significant.

What manufacturing and IP barriers affect FOSAMAX reformulation?

Manufacturing barriers include alendronate’s ionic character, potential sensitivity to process conditions, low-dose vitamin D distribution in combination products, tablet size, and control of impurities.

Key development controls include:

• API particle-size distribution.
• Water content and hygroscopicity.
• Granulation endpoint.
• Blend uniformity.
• Lubrication time.
• Tablet hardness and friability.
• Disintegration and dissolution.
• Vitamin D assay uniformity.
• Packaging moisture ingress.
• Long-term and accelerated stability.

IP barriers are more manageable because the foundational patents have expired. Freedom-to-operate analysis should still cover live formulation patents, excipient supplier patents, delivery-device claims, packaging patents, and jurisdiction-specific rights.

Key Takeaways

• FOSAMAX is a mature alendronate product with expired core U.S. exclusivity.
• Standard generic tablets offer limited patent and pricing protection.
• The strongest excipient opportunities address swallowability, rapid dispersion, taste, liquid dosing, and alendronate-vitamin D stability.
• Novel excipient systems should be supported by comparative technical or clinical evidence.
• Conventional products may qualify for the ANDA pathway; materially different dosage forms or claims may require 505(b)(2).
• Commercial returns are more likely from manufacturing efficiency, private-label supply, or adherence-focused differentiation than from premium pricing alone.
• A defensible new patent estate should combine composition, process, packaging, and method-of-use claims.
• Generic launch risk is primarily driven by price competition, supply reliability, bioequivalence, stability, and weak reimbursement differentiation.

FAQs

Can a new excipient make a generic FOSAMAX product patentable?

Yes, but the excipient change must produce a non-obvious technical result. A routine filler or lubricant substitution generally has weak patent value without unexpected stability, dissolution, tolerability, or manufacturing data.

Is an alendronate orally disintegrating tablet commercially attractive?

It can be attractive for patients with swallowing difficulty, but the product must preserve dose accuracy, acceptable taste, rapid dispersion, and correct administration with water. The commercial advantage must exceed the cost of a more complex dosage form.

Does FOSAMAX Plus D still have meaningful formulation protection?

Its original commercial protection has largely expired. A new alendronate-vitamin D formulation could obtain protection if it solves a specific stability, uniformity, or dosing problem that is not obvious from prior art.

Can a liquid alendronate product command a premium price?

Usually only if it demonstrates a clear patient or caregiver benefit. Standard generic alendronate and inexpensive vitamin D alternatives place a strong ceiling on pricing.

Are biosimilar issues relevant to FOSAMAX?

No. Alendronate is a small-molecule drug, not a biologic. Biosimilar pathways do not apply. Competition occurs through generic drug approval pathways, including ANDAs and, for some differentiated products, 505(b)(2) applications.

References

1. U.S. Food and Drug Administration. (2024). FOSAMAX (alendronate sodium) prescribing information. Merck Sharp & Dohme LLC.

2. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations. FDA.

3. U.S. Patent and Trademark Office. (1990). U.S. Patent No. 4,922,007: Diphosphonic acids and pharmaceutical compositions. U.S. Department of Commerce.

4. National Library of Medicine. (2025). DailyMed: FOSAMAX and FOSAMAX Plus D labeling. U.S. National Library of Medicine.

5. U.S. Food and Drug Administration. (2024). Guidance for industry: ANDAs for certain highly soluble, highly permeable drugs. FDA.